← Back to Search

Keratoprosthesis

CorNeat KPro for Corneal Diseases

N/A
Waitlist Available
Research Sponsored by CorNeat Vision Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-months
Awards & highlights

Study Summary

This trial is testing a new synthetic cornea to see if it is safe and effective in treating corneal blindness.

Eligible Conditions
  • Corneal Diseases
  • Corneal Opacity
  • Corneal Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety Endpoint as determined by the frequency and severity of all unanticipated adverse device-related events (UADE)
Secondary outcome measures
Primary effectiveness Endpoint - Device retention rate
Secondary effectiveness Endpoint - Improvement in BCDVA

Trial Design

1Treatment groups
Experimental Treatment
Group I: CorNeat KProExperimental Treatment1 Intervention
Intraocular implantation of the CorNeat KPro

Find a Location

Who is running the clinical trial?

CorNeat Vision Ltd.Lead Sponsor
3 Previous Clinical Trials
128 Total Patients Enrolled
1 Trials studying Corneal Diseases
40 Patients Enrolled for Corneal Diseases

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment open to people under the age of twenty for this experiment?

"This clinical trial requires applicants to be aged between 18 and 80. For those patients outside of this age range, there are 13 trials catered specifically for minors and 39 studies tailored towards seniors."

Answered by AI

What is the estimated participant count for this trial?

"To meet the requirements of this trial, 40 individuals who fit the study's eligibility standards must participate. These participants can come from several different locations such as Cincinnati Eye Institute in Edgewood and UHN - University Health Network in Toronto."

Answered by AI

How many healthcare locations in Canada are currently engaged with this trial?

"Patients can be enrolled in this trial at Cincinnati Eye Institute located in Edgewood, Kentucky; UHN - University Health Network situated in Toronto, Ontario; and the University of British Columbia based out of Vancouver, British Columbia. Plus there are four other participating locations."

Answered by AI

Is it possible for me to partake in this medical research?

"This medical trial is enrolling 40 individuals aged between 18 and 80 who suffer from corneal opacity. Expectant mothers must provide a negative pregnancy test at the screening stage, while all participants are required to have an understanding of light in each quadrant. Male or female candidates need to be capable and willing to attend scheduled visits and follow through with associated study requirements. Those ineligible for keratoplasty due to prior failed transplantations, herpetic keratitis, vascularized scarring, OCP and other conditions may qualify for this project as long as they do not possess pseudophakia."

Answered by AI

Are recruitments for this experiment open at the moment?

"Data is readily available from clinicaltrials.gov that confirms the current recruitment status of this medical trial. The initial posting was on March 1, 2021 and subsequent updates were made as recently as April 24, 2022."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
UCLA - The Jules Stein Eye Institute
Cincinnati Eye Institute
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

I've had 3 other cornea transplants and also 2 cross-linking treatments that eventually had failed over time. Was looking to see what the latest developments in this medical issue to see if there is a longer lasting solution.
PatientReceived 1 prior treatment
~2 spots leftby May 2025